Novartis Receives Full FDA Approval for Fabhalta in Kidney Disease

Key Facts

In a move that strengthens Novartis' position in the specialty pharmaceuticals sector, the U.S. Food and Drug Administration (FDA) has granted full traditional approval for Fabhalta. This drug stands as the first-in-class oral treatment designed to slow the decline of kidney function in adults with IgA nephropathy (IgAN). The approval transitions the medication from accelerated to traditional status based on its proven efficacy in delaying the need for dialysis.

This regulatory milestone places Novartis in a strong competitive position against peers like Travere Therapeutics, which markets Filspari in the same therapeutic area. Per market data, the rare kidney disease sector is seeing increased growth as firms race to provide non-invasive alternatives. Recent clinical trial data for Novartis showed a significant reduction in proteinuria, a key marker of disease progression, compared to standard care (per company earnings reports).

Shares of NVS closed at $152.73 (close July 16, 2026), with the stock trading within a daily range of $150.21 to $153.18. Investors are now monitoring the speed of market adoption in the U.S. following this full approval. According to the economic calendar, there are no major sector-specific catalysts scheduled for the next seven days, leaving the focus on the company's upcoming quarterly sales performance.